Abstract
Research of the antimicrobial action of model specimens of a potential drug in various fixed combinations and the advent of specific antimycotic activity of model samples of a new, combined, potential drug and medicine product, selected as a reference "Neo-Penotran®" (Exeltis Healthcare S.L., Spain).Aim of the research was to determine the susceptibility of in vitro Candida spp. isolates to a new combined drug containing a substance with an antimycotic activity for the treatment of vaginal candidiasis.Materials and methods. Candida albicans (ATCC 10231) and Candida albicans (clinical isolate) from the material, urogenital pathways from women with a diagnosis of candidiasis were used to prove the activity and determine the sensitivity.The study of antimicrobial activity was carried out using the serial dilutions method in trypticase-soybean broth, which allowed to ensure a uniform distribution of the drug in the nutrient medium in contact with pathogenic strains, and the subsequent transfer to Petri dishes on Sabouraud agar - the most accurate evaluation of the results.Results of the study of the antimycotic activity of 7 model specimens showed antimycotic activity in only 3 model specimens in relation to both the reference strain Candida albicans ATCC 10231 and the clinical strain of Candida albicans.Conclusions. The results of the studies indicate that there is a strong in vitro antimycotic effect of the new potential combined drug against pathogenic test strains: Candida albicans ATCC 10231, Candida albicans (clinical isolate), which is not inferior to the selected reference medicine. Minimum inhibitory concentration of the test drug in vitro was established for pathogenic test strains: Candida albicans ATCC 10231, Candida albicans (clinical isolate). The study of various combinations and concentrations of the combined drug made it possible to exclude the presence of negative interaction between components of the experimental specimen and to select the most promising and effective sample for further experimental studies of combinations of antimycotics for intravaginal use
Highlights
Diseases with infectious etiology of the reproductive system of a woman are one of the most important medical and social problems in the structure of which the defeat of fungal nature play an essential role
There is practically no statistically reliable information on the prevalence of vaginal candidiasis (VC), since in most cases the disease is not isolated from other dysbiotic processes that are often recorded in women's vaginal biotope
Candida albicans (ATCC 10231) derived from the UCM (Ukrainian Collection of Microorganisms, Institute of Microbiology and Virology of the National Academy of Sciences of Ukraine) and Candida albicans from the material, urogenital tracts from women with a diagnosis of candidiasis obtained in Institute of urology, NAMS of Ukraine
Summary
Diseases with infectious etiology of the reproductive system of a woman are one of the most important medical and social problems in the structure of which the defeat of fungal nature play an essential role. Inflammatory diseases of the pelvic organs occupy one of the leading places in the structure of gynecological pathology and are detected in 60–65 % of all gynecological patients Inadequate treatment of these diseases leads to a chronic process, forming the basis of pathological conditions, which subsequently violate the fertile function of women. Vaginitis occurs due to the combination of several factors, for example, bacterial and fungal nature, accounting for 10 to 30 % of all cases of infectious diseases in gynecology. 5. Formulation of goals (tasks) of article Aim of the research – to establish the sensitivity of in vitro Candida spp. isolates to a new combined drug containing a substance with an antimycotic effect for the treatment of vaginal candidiasis. Presentation of the main research material (methods and objects) with the justification of the results
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
